A Study Comparing the Effectiveness of Two Bowel Cleansing Agents for Colonoscopy Preparation in Patients with Hematochezia

A prospective, randomized, multicenter trial to offer evidence for the choice of bowel preparation in hematochezia patients: Polyethylene Glycol with Ascorbic Acid versus Oral Sulfate Solution

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0010883

Enrollment

196

Registered

2025-08-12

Start date

2023-08-14

Completion date

Unknown

Last updated

2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : - Intervention Group (OSS): • Drug Name: Oral Sulfate Solution (OSS, Oral Sulfate Solution, OraPang) • Dose: OraPang 24 tablets • Administration Method: Split dose (2 divided doses) o First dos

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Participants aged 20 to 85 years who presented with hematochezia and are scheduled to undergo diagnostic colonoscopy after providing informed consent

Exclusion criteria

Exclusion criteria: 1. Individuals who have undergone colectomy 2. Patients with congestive heart failure or those who experienced acute myocardial infarction within the past 6 months 3. Patients classified as American Society of Anesthesiologists (ASA) class III or higher (e.g., severe uncontrolled hypertension, severe uncontrolled diabetes, chronic kidney disease stage 4, uncontrolled asthma) 4. Patients with a history of liver cirrhosis, ascites, chronic kidney disease (stage 4 [GFR 15–29] or higher), inflammatory bowel disease, or severe inflammatory conditions 5. Individuals with disabilities (cognitive or intellectual disabilities) or pregnant women 6. Patients with paralytic ileus, bowel obstruction, or toxic megacolon 7. Individuals with severely unstable vital signs that preclude colonoscopy 8. Patients who refuse to sign the informed consent form 9. Patients with hypersensitivity to this drug or any of its components 10. Patients with gastrointestinal perforation or gastric retention 11. Patients with severe dehydration 12. Any other individuals deemed inappropriate for participation in the clinical trial by the investigator

Design outcomes

Primary

Measure	Time frame
Proportion of participants achieving adequate bowel cleansing assessed using the Boston Bowel Preparation Scale (BBPS)	—

Secondary

Measure	Time frame
Harefield Cleansing Scale (HCS) score;Medication Compliance;Medication Acceptability;Safety Assessment;Adenoma and Polyp Detection Rate;Identification of Bleeding Site and Hemostasis	—

Countries

Korea, Republic of

Contacts

Public ContactSu Young Kim

Yonsei University, Wonju Severance Christian Hospital

breeze1212@naver.com+82-33-741-1229

Outcome results